--------------------------------------------------------------------------------

 
Exhibit 10.12
 
 
AMENDMENT TO LICENSE AGREEMENT
 
This Amendment ("Amendment'"). effective as of ________, 2011. modifies the
terms of the License Agreement ("Agreement") between BioZone Laboratories. Inc.
and BetaZone Laboratories LLC dated November 7. 2006.
 
Whereas:
 
A.
BioZone Phamlaceutical. Inc .. a Delaware corporation having a principal place
of business at 580 Garcia Avenue. Pittsburg. CA 94565 ("BPI") is the successor
in interest to BioZone Laboratories. Inc. ("BU") and the assignee of the BLI’s
entire interest under the Agreement:

 
B.
BetaZone Laboratories LLC ("BetaZone") has developed the ophthalmic products
listed in the attached schedule ("Existing Ophthalmic Products") pursuant to the
Agreement: and

 
C.
BLI wishes to enter into a new separate license agreement relating to ophthalmic
products with a third party;

 
Therefore. BPI and BetaZone agree as follows.
 
1.
BetaZone shall have the right to continue to market and sell Existing Ophthalmic
Products pursuant to the Agreement. Such right shall include all other rights
necessary to implement such marketing and sales activity. including the right to
continue manufacture of Existing Ophthalmic Products pursuant to the Agreement.

 
2.
BetaZone shall not develop. market or sell any new therapeutic and/or
preventative ophthalmic products incorporating the confidential information
and/or Know-How as defined in the Agreement.

 

 
Signed:
   
/s/ Camillo Rey
 
/s/ Brian Keller
Managing Director
 
CEO
BetaZone
 
BPI
     
04/04/2011
   
Date
 
Date
     

 

 
 

--------------------------------------------------------------------------------